Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
LSL Pharma Group Inc ( (TSE:LSL) ) has shared an update.
LSL Pharma Group Inc. has announced the early redemption of its 11% unsecured convertible debentures, originally due in 2028, with a total principal amount of $3,288,000. The redemption, set for August 4, 2025, will see debenture holders receiving a redemption price of $10.40 per $10 principal amount, plus accrued interest. This move may impact the company’s financial strategy and market positioning, as it reflects a proactive approach to managing its debt obligations.
More about LSL Pharma Group Inc
LSL Pharma Group Inc. is a Canadian integrated pharmaceutical company specializing in the development, manufacturing, and commercialization of high-quality sterile ophthalmic pharmaceutical products, as well as pharmaceutical, cosmetic, and natural health products in various dosage forms. The company comprises entities such as Steri-Med Pharma Inc., LSL Laboratory Inc., Virage Santé Inc., and Dermolab Pharma Ltd.
Average Trading Volume: 47,153
Technical Sentiment Signal: Sell
See more insights into LSL stock on TipRanks’ Stock Analysis page.